ERAS
HOLD / NEUTRALMeanRevComposite
46.60
Technical
92.50
Fundamental
31.40
Rank
—
Price
19.50
Hurst
0.24
As of
Jul 15, 2026
Daily
Erasca, Inc.
HealthcareBiotechnologyErasca is a clinical-stage oncology company developing targeted cancer treatments focused on tumors driven by RAS/MAPK pathway mutations. Its pipeline includes molecular glue and kinase inhibitor candidates designed to treat various solid tumors with RAS and KRAS mutations, as well as an antibody therapy targeting EGFR-driven cancers. The company has established partnerships with multiple organizations to advance its drug candidates through development and commercialization.
Market cap
$5.4B
P/E (trailing)
—
P/E (forward)
-24.62
PEG ratio
—
Dividend yield
—
Beta
0.65
52w range
1.75 – 24.28
Return on equity
-78.25%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 15.36 (+721.4%) · range 1.77–22.47
Cycle position
28/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 53 · MODERATE · exit proximity 0
Conviction
39/ 100 · maturity 29%
VScore.1612
Buildup.2844
EMA entry setup.3553
Fundamentals.2131
Volume profile
POC
10.10
Price vs POC
+52.0%
Overhead supply
57%
Runway
+16.5%
Value area 8.70–18.36 · 57% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -12.61% | -8.23% | mature |
| 40d | -24.60% | -8.23% | mature |